Pharmacogenomics
Why the Same Pill Hits Everyone Differently
The antidepressant your doctor prescribed might work beautifully for your colleague and do almost nothing for you — and the reason is written in your DNA.
The Idea
Medicine has long operated on a statistical fiction: that the average response to a drug in a clinical trial tells us something useful about how you, specifically, will respond. It often doesn't. Pharmacogenomics — the study of how your genes influence your response to medications — is quietly dismantling that assumption. The mechanism is more elegant than it first sounds. Your liver contains a family of enzymes, the cytochrome P450 group, responsible for metabolising a huge proportion of common drugs. The genes encoding these enzymes vary considerably between people. Some people are 'poor metabolisers' — their version of the enzyme works slowly, so a standard dose accumulates in the body, intensifying effects and side effects. Others are 'ultra-rapid metabolisers' — the drug clears their system so fast it barely registers. Neither group is broken. They just have different genetic instructions. This isn't marginal variation. For codeine, for instance, ultra-rapid metabolisers convert it to morphine so quickly they can reach dangerous blood concentrations from a standard dose. For certain antidepressants like citalopram, the difference between a poor and rapid metaboliser can mean the gap between toxicity and therapeutic failure at the exact same prescription. The same logic extends well beyond metabolism. Some genetic variants affect how strongly a drug binds to its target receptor, or how efficiently your cells pump it back out. Pharmacogenomics maps this entire landscape — not to tell you which drug is 'best' in the abstract, but which one is most likely to work for your particular biology.
In the World
In 2011, the US Food and Drug Administration updated the label for clopidogrel — a widely prescribed blood thinner given to millions of people after heart attacks and stent procedures — with a striking warning. Roughly 30% of people carry a variant of the CYP2C19 gene that makes them poor metabolisers of the drug. For these patients, clopidogrel doesn't convert efficiently into its active form, meaning the medication they're taking to prevent another cardiac event is providing significantly reduced protection. For years, they had been prescribed the standard dose without anyone checking whether their biology could actually use it. This wasn't a fringe case. It was one of the most prescribed drugs in the world, and a substantial minority of patients were deriving little benefit — a fact invisible to both doctor and patient without genetic testing. The field has since moved quickly. Vanderbilt University Medical Center launched one of the earliest large-scale pharmacogenomics implementation programmes, pre-emptively genotyping thousands of patients and embedding the results directly into their medical records. When a doctor went to prescribe a relevant medication, an alert would appear: this patient is an ultra-rapid metaboliser — consider an alternative. Early results showed measurable reductions in adverse drug events and prescription changes that would never have happened otherwise. What Vanderbilt demonstrated is that this isn't futuristic medicine. The tests exist, the knowledge exists, and the infrastructure to act on it is buildable. The main gap is still, stubbornly, routine adoption.
Why It Matters
Most of us have a fraught relationship with medication — a trial-and-error process that can feel mysterious and sometimes demoralising. An antidepressant that causes intolerable side effects. A painkiller that seems not to touch the pain. A sleep aid that leaves you groggy for half the next day. These experiences are often framed as sensitivity, tolerance, or placebo, when the real explanation may be sitting in your genome. Knowing your pharmacogenomic profile doesn't mean you manage your own prescriptions — it means you bring more useful information into the conversation with whoever is helping you. Increasingly, direct-to-consumer genetic tests include some pharmacogenomic data, though the depth and clinical reliability varies. More meaningfully, specialised pharmacogenomic panels are becoming available through healthcare providers, particularly for psychiatric medications where the trial-and-error cycle is notoriously lengthy and costly. The broader shift pharmacogenomics represents is worth sitting with: from population-level medicine toward something genuinely individual. Not because your uniqueness is philosophically significant — though it may be — but because your body processes the world differently than the person next to you, and that difference is measurable.
A Question to Ponder
If you've ever had an unexpected reaction to a medication — stronger, weaker, or stranger than the doctor anticipated — what would it change to know that it was always going to happen that way for you?
Get a new one of these every morning.
Start learning with Thinkable